What Dalfaz Uno treats: main uses and benefits

Dalfaz Uno is a medication primarily prescribed to manage the functional symptoms associated with benign prostatic hyperplasia (BPH), a condition characterized by the non-cancerous enlargement of the prostate gland.

Primary Indications

The medication is used to address urinary difficulties that occur when an enlarged prostate exerts pressure on the urethra. By targeting specific receptors in the smooth muscles of the prostate, bladder neck, and urethra, the treatment helps to reduce the resistance to urine flow.

Core Benefits

Patients prescribed Dalfaz Uno typically experience improvements in the following areas:

• Reduction of Urinary Obstruction: The treatment facilitates the relaxation of muscular tension in the urinary tract, making it easier to initiate urination.
• Improvement in Flow Rate: By decreasing the pressure on the urethra, the medication helps to increase the strength and consistency of the urinary stream.
• Relief of Storage Symptoms: It can help reduce the frequency of urination, the urgent need to urinate, and the necessity of waking up during the night to use the bathroom.
• Management of Acute Urinary Retention: In some clinical scenarios, this medication is used as an adjunctive therapy to assist in the management of sudden inability to urinate, often in conjunction with catheterization.

Mechanism Summary

Dalfaz Uno belongs to a class of drugs known as alpha-1 blockers. Its primary benefit is its uroselective nature, meaning it focuses its action on the urinary system to alleviate physical discomfort and improve quality of life without addressing the actual size of the prostate gland itself.

The eligibility for Dalfaz Uno (alfuzosin extended-release) is strictly defined by official regulatory labeling across several key areas. The medicine is not indicated for use in women and is not recommended for the pediatric population (children and adolescents), with its approved use restricted solely to adult men. Older adults are generally eligible, though increased sensitivity in some individuals cannot be ruled out.

The following populations are absolutely contraindicated (must not use the medicine):

• Patients with moderate or severe hepatic impairment (liver disease).
• Patients with known hypersensitivity to alfuzosin or any component of the tablet.
• Patients receiving concomitant treatment with other alpha-1 antagonists or potent CYP3A4 inhibitors (such as ketoconazole or ritonavir).

Use requires caution and special consideration in other specific groups. This includes individuals with severe renal impairment (creatinine clearance less than 30 mL/min) due to limited safety data in this population. Caution is also advised for patients with coronary insufficiency and those with a history of or predisposition to QTc prolongation.

Dalfaz Uno's interaction profile is based on restrictions related to its metabolism and potential for additive effects, as detailed in regulatory documents.

Interaction scope

Category	Official Interaction Entities
Medicinal product categories with documented interactions	Potent CYP3A4 Inhibitors; Other Alpha-1 Adrenergic Antagonists; Antihypertensive Agents; Nitrates; Phosphodiesterase-5 (PDE5) Inhibitors.
Mechanistic basis of interactions (only if stated in label)	Pharmacokinetic interaction: Metabolism via the CYP3A4 enzyme. Pharmacodynamic interaction: Additive alpha1-receptor blockade.
Timing-based interaction rules (if applicable)	Must be taken immediately after the same meal each day to prevent a documented 50% lower absorption extent under fasting conditions.
Population-specific interaction notes (if applicable)	Hepatic Impairment: Contraindicated in patients with moderate or severe hepatic impairment due to reduced clearance, resulting in documented three- to four-fold higher plasma concentrations.

Official interaction statements

Co-administration of Dalfaz Uno is formally contraindicated with potent inhibitors of the CYP3A4 enzyme, including specific antifungals like Ketoconazole and antivirals such as Ritonavir, because these agents are documented to substantially increase alfuzosin exposure. Combining this medicine with any other Alpha-1 Adrenergic Antagonist is also prohibited due to the risk of additive hypotensive effects. Caution is advised when co-administering with antihypertensive agents, nitrates, or PDE5 inhibitors, due to the documented increased risk of symptomatic hypotension.

Connection to the overall interaction profile

Regulatory documents define the interaction structure via formal contraindications concerning both metabolic (CYP3A4 inhibition) and pharmacodynamic (alpha1-blockade) mechanisms, and by setting timing constraints to ensure consistent drug absorption. This structure highlights specific substances and conditions that lead to clinically significant alterations in alfuzosin exposure or additive hypotensive risks.

Selective Alpha-1 Receptor Competitive Blockade

Alfuzosin's mechanism begins at the molecular level with the competitive antagonism of the Alpha-1 (alpha1) Adrenergic Receptors, primarily the mathbfalpha1A subtype, located on the smooth muscle of the prostate and bladder neck. This interaction prevents the binding of the natural signaling molecule, Norepinephrine, preventing the initiation of the muscle contraction signal.

Inhibition of the Contraction Signal Cascade

By blocking the alpha1 receptor, Alfuzosin halts the downstream Phospholipase C (PLC) signaling cascade, which normally causes the necessary release of calcium ions ( Ca^2+) within the muscle cells. This action prevents the rise of intracellular calcium, thereby directly inhibiting the sustained contraction (or tone) of the muscle tissue.

Functional Consequence: Dynamic Smooth Muscle Resistance

The physiological consequence of sustained alpha1-blockade and inhibited signal transduction is active smooth muscle relaxation in the lower urinary tract. This action focuses on reducing the dynamic component of resistance—the tension exerted by the muscle—resulting in the functional widening of the urinary outflow channel. The specialized extended-release formulation facilitates continuous receptor occupancy over 24 hours, maintaining reduced muscle tone.

How to Use Dalfaz Uno

This section outlines the instructions for the administration of Dalfaz Uno (alfuzosin extended-release 10 mg).

---

Administration Scope

Instruction	Detail
Route of administration	Oral
Dosing schedule	One 10 mg extended-release tablet
Timing in relation to meals	Must be taken immediately after a meal (mandatory)
Age-group administration rules	Adults 18 years and older: Standard 10 mg dose. Pediatrics: Not indicated for use.
Missed-dose rules	If a dose is missed, skip that dose and take the next dose at the regular time.
Special procedural conditions	Must be taken with the same meal each day for consistency. Not recommended in cases of severe renal or hepatic impairment.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral (Tablet)
Frequency pattern	Once daily
Use-context constraints	Mandatory post-meal timing; Mandatory swallow whole (to preserve the extended-release mechanism).

---

Resulting Procedural Structure

Official step sequence:

• Take one 10 mg extended-release tablet once daily.
• Ingest the tablet immediately after a meal and ideally with the same meal each day.
• Swallow the tablet whole with liquid; do not crush, chew, split, or divide the tablet.

Connection to the overall use protocol: The instructions establish a structured, non-titrated, once-daily oral regimen that is fundamentally dependent on concurrent food intake. These rules define the precise manner in which the extended-release tablet must be administered to achieve the intended sustained delivery of alfuzosin, mandating the swallowing of the tablet whole to preserve its controlled-release pharmaceutical design.

Dalfaz Uno: Recent Clinical Evidence

Dalfaz Uno (alfuzosin) is an alpha-1 adrenoceptor antagonist utilized in the management of symptoms associated with Benign Prostatic Hyperplasia (BPH). Research has focused on its efficacy in improving urinary function.

Overview of Efficacy Studies

Clinical trials involving alfuzosin have primarily centered on its effect on the lower urinary tract symptoms (LUTS) in men with BPH. The drug's action is associated with the relaxation of smooth muscles in the prostate, prostatic capsule, and bladder neck, which can lead to an improvement in urine flow rate.

• Treatment of Functional Disorders: Studies evaluating the long-term use of alfuzosin report findings related to the relief of functional voiding symptoms when surgical treatment for BPH is not immediately pursued.
• Acute Urinary Retention (AUR): Alfuzosin has also been studied as an adjunctive treatment for patients requiring a catheter due to acute urinary retention caused by BPH. Research protocols in this context generally involve continued treatment for a short duration while the catheter is in place and after its removal.

Key Research Limitations

Clinical data and prescribing information highlight specific areas requiring caution or further investigation:

• Blood Pressure Monitoring: Due to its mechanism as an alpha-blocker, studies note that the drug may be associated with orthostatic hypotension (a drop in blood pressure upon standing). This finding requires attention, particularly in elderly individuals or those taking other blood pressure-lowering medications.
• Drug Interactions: Evidence indicates that the drug's metabolism involves the CYP3A4 enzyme. Consequently, research suggests the potential for interactions when used concurrently with strong CYP3A4 inhibitors (e.g., certain antifungal or antiviral agents) or other alpha-1 adrenoceptor blocking agents. Patients and healthcare providers should refer to official sources for complete interaction information.

Common questions about Dalfaz Uno (FAQ)

Q: Is Dalfaz Uno the same kind of medicine as Dalfaz?

Both Dalfaz Uno and Dalfaz contain the same active ingredient, alfuzosin. However, official product information indicates that the name 'Uno' specifically identifies a once-daily, extended-release tablet formulation. This specialized design means the medicine is released slowly over time, which may differ from older or immediate-release versions of alfuzosin.

Q: How fast does Dalfaz Uno typically start working?

Pharmacokinetic studies indicate that the concentration of the drug reaches its peak level in the body about eight hours after it is taken. Studies report findings that suggest improvements in urinary flow rates may be seen within the first 24 hours of starting treatment and with continued use.

Q: What are the most common things people feel when they first start Dalfaz Uno?

According to the official product information, the most commonly reported effects in clinical studies include dizziness, headache, and a feeling of general fatigue or weakness. Regulatory documents note that these symptoms are often most noticeable when treatment is first started.

Q: Are there any specific foods or drinks to avoid while taking Dalfaz Uno?

Official warnings advise against consuming grapefruit or grapefruit juice because these can interfere with how the body processes the medicine, potentially increasing its levels. Official warnings note that alcohol intake may increase the risk of side effects such as dizziness or fainting.

Q: What is the difference between Dalfaz Uno and similar medicines I see advertised?

Dalfaz Uno belongs to a class of medicines called Alpha-1 Adrenergic Receptor Antagonists (or alpha1-blockers). This defines a class of medicines with a similar mechanism of action related to muscle relaxation. They may differ in factors like their chemical structure, how they are metabolized them, or their overall documented effect on blood pressure.

Q: Will Dalfaz Uno make me feel tired or drowsy?

Yes, official regulatory documents list fatigue (asthenia or tiredness) as one of the most commonly reported side effects. Somnolence, which refers to a state of drowsiness, is also noted as an uncommon but documented adverse effect.

Q: What are the potential effects of Dalfaz Uno on sexual function?

Reported effects on the reproductive system in clinical studies include impotence (difficulty getting or maintaining an erection) and a decrease in sexual ability or desire. A very rare, serious event documented in post-market reports is Priapism (a prolonged and painful erection).

Q: Can Dalfaz Uno be used alongside medicines for diabetes?

The official product label does not specifically name diabetes medicines as a category of concern. However, caution is advised with all medicines that lower blood pressure, as Dalfaz Uno may enhance this effect. Additionally, co-administration with certain potent enzyme inhibitors is officially prohibited.

Q: Does taking Dalfaz Uno interfere with driving or operating machinery?

Official warnings state that side effects such as dizziness, fainting, or fatigue may occur, especially when starting treatment. Patients should consider the risks of these side effects before engaging in driving or operating machinery.

Q: How long does the effect of one tablet of Dalfaz Uno last?

Dalfaz Uno is an extended-release formulation, meaning the tablet is specifically designed to deliver the medicine continuously over a 24-hour period. This ensures that the drug levels remain stable throughout the day and night after a single daily dose.

Q: Is it normal to feel a change in nasal congestion after starting Dalfaz Uno?

Yes. According to clinical data and official documentation, a runny or stuffy nose (rhinitis or nasal congestion) has been reported as an adverse reaction. This may be related to the way the medicine affects blood flow.

Q: Are there specific symptoms that Dalfaz Uno is not intended to treat?

Official labeling indicates that Dalfaz Uno is only approved for the symptomatic treatment of Benign Prostatic Hyperplasia (BPH) and, in some cases, Acute Urinary Retention (AUR) related to BPH. The medicine is not indicated for treating other urinary issues caused by conditions unrelated to the prostate.

Q: Are there different strengths of Dalfaz Uno available?

The single approved strength of the extended-release tablet is 10 mg. Regulatory documents and product monographs only describe this one strength for the branded extended-release product.

Q: Why is Dalfaz Uno only available by prescription?

The requirement for a prescription is established because the medicine carries the potential for serious risks that necessitate clinical evaluation and monitoring. These risks include potential postural hypotension (dizziness or fainting) and the need to verify specific contraindications related to other medicines and existing health conditions.

Q: Does Dalfaz Uno cause problems with vision?

The official product label includes a warning about a documented risk called Intraoperative Floppy Iris Syndrome (IFIS), which is a potential complication during cataract or glaucoma surgery. Additionally, blurred vision has been reported, sometimes in association with low blood pressure effects of the medicine.

How to Store and Dispose of Dalfaz Uno

Dalfaz Uno (alfuzosin extended-release tablets) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medicine must be kept in its original, tightly closed container and requires protection from both moisture and light.

Storage Protection

The tablets should not be stored in high-humidity areas, such as a bathroom. To prevent accidental ingestion, all unused medication must be kept strictly out of the reach of children and pets.

Official Disposal Rules

Official guidelines prohibit disposing of Dalfaz Uno by flushing the tablets down the toilet or pouring them into a drain. Unused or expired tablets should be discarded through a drug take-back program. If a take-back program is unavailable, mix the medicine with an undesirable substance (such as dirt) and place it in a sealed bag for household trash disposal.